GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Taiwan Bio Therapeutics Co Ltd (ROCO:6892) » Definitions » Asset Turnover

Taiwan Bio Therapeutics Co (ROCO:6892) Asset Turnover : 0.03 (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Taiwan Bio Therapeutics Co Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Taiwan Bio Therapeutics Co's Revenue for the six months ended in Jun. 2024 was NT$27.7 Mil. Taiwan Bio Therapeutics Co's Total Assets for the quarter that ended in Jun. 2024 was NT$1,075.2 Mil. Therefore, Taiwan Bio Therapeutics Co's Asset Turnover for the quarter that ended in Jun. 2024 was 0.03.

Asset Turnover is linked to ROE % through Du Pont Formula. Taiwan Bio Therapeutics Co's annualized ROE % for the quarter that ended in Jun. 2024 was -36.81%. It is also linked to ROA % through Du Pont Formula. Taiwan Bio Therapeutics Co's annualized ROA % for the quarter that ended in Jun. 2024 was -25.66%.


Taiwan Bio Therapeutics Co Asset Turnover Historical Data

The historical data trend for Taiwan Bio Therapeutics Co's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Taiwan Bio Therapeutics Co Asset Turnover Chart

Taiwan Bio Therapeutics Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
- - 0.07 0.06 0.09

Taiwan Bio Therapeutics Co Semi-Annual Data
Dec19 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Asset Turnover Get a 7-Day Free Trial Premium Member Only 0.04 0.01 0.01 0.07 0.03

Competitive Comparison of Taiwan Bio Therapeutics Co's Asset Turnover

For the Biotechnology subindustry, Taiwan Bio Therapeutics Co's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Taiwan Bio Therapeutics Co's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Taiwan Bio Therapeutics Co's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Taiwan Bio Therapeutics Co's Asset Turnover falls into.



Taiwan Bio Therapeutics Co Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Taiwan Bio Therapeutics Co's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=85.47/( (871.01+941.761)/ 2 )
=85.47/906.3855
=0.09

Taiwan Bio Therapeutics Co's Asset Turnover for the quarter that ended in Jun. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Jun. 2024 )/( (Total Assets (Q: Dec. 2023 )+Total Assets (Q: Jun. 2024 ))/ count )
=27.724/( (941.761+1208.679)/ 2 )
=27.724/1075.22
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Taiwan Bio Therapeutics Co  (ROCO:6892) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Taiwan Bio Therapeutics Co's annulized ROE % for the quarter that ended in Jun. 2024 is

ROE %**(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=-275.91/749.6445
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-275.91 / 55.448)*(55.448 / 1075.22)*(1075.22/ 749.6445)
=Net Margin %*Asset Turnover*Equity Multiplier
=-497.6 %*0.0516*1.4343
=ROA %*Equity Multiplier
=-25.66 %*1.4343
=-36.81 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2024) net income data. The Revenue data used here is two times the semi-annual (Jun. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Taiwan Bio Therapeutics Co's annulized ROA % for the quarter that ended in Jun. 2024 is

ROA %(Q: Jun. 2024 )
=Net Income/Total Assets
=-275.91/1075.22
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-275.91 / 55.448)*(55.448 / 1075.22)
=Net Margin %*Asset Turnover
=-497.6 %*0.0516
=-25.66 %

Note: The Net Income data used here is two times the semi-annual (Jun. 2024) net income data. The Revenue data used here is two times the semi-annual (Jun. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Taiwan Bio Therapeutics Co Asset Turnover Related Terms

Thank you for viewing the detailed overview of Taiwan Bio Therapeutics Co's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Taiwan Bio Therapeutics Co Business Description

Traded in Other Exchanges
N/A
Address
No. 18, Lane 120, Hu Road, Section 1, 6th Floor, Neihu District, Taipei, TWN
Taiwan Bio Therapeutics Co Ltd is a regenerative medicine company specializing in the development of new cell medicines. It provides cell product process development and foundry (CDMO/CMO) services.

Taiwan Bio Therapeutics Co Headlines

No Headlines